Reading and Resources
Support Organizations
Skin Cancer Champions. http://www.skincancerchampions.org
Online Resources
American Cancer Society. Basal and Squamous Cell Skin Cancer. https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html
Skin Cancer Foundation. Basal Cell Carcinoma Overview. https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/
Memorial Sloan Kettering Cancer Center. Basal Cell Carcinoma. https://www.mskcc.org/cancer-care/types/basal-cell-carcinoma
American Academy of Dermatology. Skin Cancer Types. Basal Cell Carcinoma Overview. Last updated October 1, 2025. https://www.aad.org/public/diseases/skin-cancer/types/common/bcc
Treatment Recommendations
American Academy of Dermatology Association. Skin Cancer Types. Basal Cell Carcinoma Diagnosis and Treatment. https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/treatment
National Comprehensive Cancer Network. NCCN Guidelines for Patients. Basal Cell Skin Cancer 2026. https://www.nccn.org/patients/guidelines/content/PDF/basal-cell-patient-guideline.pdf
Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of basal cell carcinoma. J Amer Acad Derm. 2018;78:540-559. https://www.jaad.org/article/S0190-9622(17)32529-X/fulltext
NIH. National Cancer Institute. Skin Cancer Treatment (PDQ®)–Health Professional Version. Updated May 12, 2025. https://www.cancer.gov/types/skin/hp/skin-treatment-pdq
Journal Articles
Bassett-Seguin N, Herms F. Update in the management of basal cell carcinoma. Acta Derm Venereol. 2020;100:adv00140. https://pubmed.ncbi.nlm.nih.gov/32346750/
Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188-2205. doi:10.1016/j.immuni.2023.09.011
https://pubmed.ncbi.nlm.nih.gov/37820582/
Kim YA, Myung S, Choi Y, et al. Ethnic-specific and UV-independent mutational signatures of basal cell carcinoma in Koreans. Int J Mol Sci. 2025;26:6941. doi:10.3390/ijms26146941
https://pubmed.ncbi.nlm.nih.gov/40725190/
Hoellwerth M, Brandlmaier M, Koelblinger P. Therapeutic approaches for advanced basal cell carcinoma: A comprehensive review. Cancers (Basel). 2024;17:68. doi:10.3390/cancers17010068
https://pubmed.ncbi.nlm.nih.gov/39796697/
Lewis K, Peris K, Sekulic A, et al. Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). J ImmunoTher Cancer. 2020;8(suppl 3):A260-A261. https://doi.org/10.1136/jitc-2020-SITC2020.0428
Morgan FC, Ruiz ES, KAria PS, et al. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol. 2020;83:832-838. https://pubmed.ncbi.nlm.nih.gov/31600531/
Naik PP, Desai MB. Oncol Ther. Basal cell carcinoma: A narrative review on contemporary diagnosis and management. Oncol Ther. 2022;10:317-335. https://pubmed.ncbi.nlm.nih.gov/35729457/
Farberg AS, Portela D, Sharma D, Kheterpal M. Evaluation of the tolerability of hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma: a narrative review of treatment strategies. Am J Clin Dermatol. 2024;25:779-794. doi:10.1007/s40257-024-00870-3
https://pubmed.ncbi.nlm.nih.gov/38896403/
Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39:1164-1178. https://pubmed.ncbi.nlm.nih.gov/35089534/
All URLs accessed April 3, 2026
